NeuroOne Announces Virtual Investor Webinar to Discuss Corporate Strategy and Technology Platform

NeuroOne Medical Technologies Corporation announced it will hold a virtual investor webinar on Thursday, March 12, 2026 at 11:30 a.m. Eastern Time. Management will provide a corporate update, discuss growth plans, and offer updates on platform technologies, applications, and commercialization efforts. The webinar will include a question-and-answer session following the presentation. This event represents an important opportunity for investors and stakeholders to gain insights into the company's strategic direction and technological advancements in neurological disorder treatment.

The company's focus on transforming surgical diagnosis and treatment of neurological disorders through its electrode technology platform makes this webinar particularly relevant. NeuroOne markets four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System for brain applications, and OneRF Trigeminal Nerve Ablation System. These technologies aim to reduce hospitalizations and surgical procedures while lowering costs and improving patient outcomes through combination diagnostic and therapeutic functions. The webinar will likely address how these products fit into the company's broader commercialization strategy and market expansion plans.

For those interested in participating, the webinar can be accessed via webcast at https://www.nmtc1.com. A playback of the call will be available through Thursday, March 26, 2026, with both telephone and webcast replay options. The availability of this replay extends the accessibility of this important corporate communication beyond the live event. This approach demonstrates the company's commitment to transparent investor relations and broad dissemination of strategic information.

The timing of this investor webinar coincides with NeuroOne's ongoing research and development efforts in drug delivery and spinal cord stimulation programs. These initiatives represent potential future growth areas for the company beyond its current FDA-cleared products. The discussion of these research programs during the webinar could provide valuable insights into the company's long-term innovation pipeline and competitive positioning in the neurological device market. Investors will be particularly interested in understanding how these development efforts align with market needs and regulatory pathways.

NeuroOne's technologies address significant challenges in neurological care, where current treatment options often involve multiple procedures and extended hospital stays. The company's platform offers minimally invasive alternatives that combine diagnostic and therapeutic functions, potentially revolutionizing how neurological disorders are managed. The investor webinar represents a crucial communication channel for explaining how these technological advantages translate into commercial opportunities and patient benefits. As medical technology continues to evolve, such updates provide essential context for evaluating NeuroOne's position within the competitive landscape and its potential for sustained growth.